Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

TPZ, PTSH, YZC, PWRM, RDY- The Latest Company News Brought To You By DrStockPick.com!

drstock-2-3

signup3m

ptsh_logo

PTS, Inc. (OTC.BB:PTSH) is a publicly traded company with one subsidiary, ThinLine Technology Group.

ThinLine IT group’s primary objective is to help small-to-midsize companies succeed at what they do best, rather than managing the vital but often distracting aspects of IT services and interactive marketing. Our comprehensive service offerings provide companies a virtual business partner who maintains the technologies that make a difference in the level of professionalism and responsiveness of customers’ experiences.

ThinLine Technology Group manages, markets and maintains the IT and VoIP infrastructure for small and medium businesses (SMB market) and provides Private Cable Operators (PCO market) private label billing and call center support. At present, the company services over 21,000 clients on behalf of Private Cable Operators and over 400 apartment properties across the United States.

The company consists of three divisions of expertise that provides one-stop solutions for customers’ technology needs across a broad spectrum of marketing, support and technology services.

**********************************************************

power3

Power3 Medical Products, Inc. (OTC.BB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, has signed a definitive agreement to acquire all of the stock of Rozetta-Cell Life Sciences, Inc. Power3 plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company in the merger. The acquisition of Rozetta-Cell is expected to be completed in October or November 2010.

Rozetta-Cell is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. The company has a robust intellectual property portfolio and has created numerous products for adult stem cell therapy that are ready for market globally. Rozetta-Cell also has several collaborations in process through which it is partnering with industry-leading adult stem cell research companies and adult stem cell vendors.

Completion of the merger is subject to customary closing conditions, including receipt by the parties of all necessary board and shareholder approvals and third party consents. There can be no assurance that these conditions will be met or that the merger will be completed.

**********************************************************

Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) reported its unaudited financial results for the quarter ended September 30, 2010 under International Financial Reporting Standards (IFRS).

Key Highlights

* Consolidated revenues are at Rs. 18.7 billion ($420 million) in Q2 FY11 versus Rs. 18.4 billion ($412 million) in Q2 FY10, a year-on-year growth of 2%.
o Revenues from Global Generics for Q2 FY11 are at Rs. 13.7 billion, a year-on-year growth of 8%.
o Revenues from PSAI are at Rs. 4.6 billion in Q2 FY11, a year-on-year decline of 14%.
* EBITDA of Rs. 4.2 billion ($95 million) in Q2 FY11, represents 23% to revenues and a year-on-year growth of 12%.
* Profit before Tax for Q2 FY11 is at Rs. 3.2 billion ($72 million), a year-on-year growth of 15%.
* Profit after Tax for Q2 FY11 is at Rs. 2.9 billion ($64 million), represents 15% to revenues and a year-on-year growth of 32%.
* During the quarter, the company launched 41 new generic products, filed 21 new product registrations and filed 13 DMFs globally.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as a pharmaceutical company. It produces finished dosage forms, active pharmaceutical ingredients and intermediates, and biotechnology products.

**********************************************************

Yanzhou Coal Mining Company, (NYSE: YZC) Summary of the unaudited results of the Company and its subsidiaries (the “Group”) for the third quarter ended 30 September 2010.

Unless otherwise specified, the currency used in this Report is Renminbi (“RMB”).

For the third quarter of 2010, the operating income of the Group was RMB9,349.376 million, representing an increase of RMB3,626.900 million or 63.4% as compared with the corresponding period last year. Net profit attributable to the Shareholders was RMB3,680.986 million, representing an increase of RMB2,556.494 million or 227.3% as compared with the corresponding period last year.

Yanzhou Coal Mining Company Limited engages in the underground mining, preparation, and sale of coal. It involves in manufacturing, washing, processing, and selling steam coal used in the electricity power sector; and metallurgical coal used with coking coal in the process of pulverized coal injection, as well as operates six coal mines.

**********************************************************

Tortoise Power and Energy Infrastructure Fund, Inc. (NYSE:TPZ) recently announced that as of October 31, 2010, the company’s unaudited total assets were approximately $204.4 million and its unaudited net asset value was $169.1 million, or $24.36 per share.

As of October 31, 2010, the company was in compliance with its asset coverage ratio under the Investment Company Act of 1940 (the 1940 Act) and basic maintenance covenants. The company’s asset coverage ratio under the 1940 Act with respect to senior securities representing indebtedness was 605 percent.

Tortoise is an investment manager specializing in listed energy infrastructure investments, such as pipeline and power companies.

**********************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (OTCPK:CRWE) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for (thirty) days of advertising for PTS Inc.(OTCPK:PTSH)

Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).

drstbc